Highlights I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:52 2024-06-28 pm EDT			5-day change	1st Jan Change
1.57 ^EUR	-0.63%		-1.26%	-5.99%

Jun. 06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
Jun. 05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	Jun. 05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	Jun. 05	CI
I-Mab Completes Business Divestiture in China	Apr. 02	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	Apr. 01	CI
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Biotech firm I-Mab to divest China operations, shift focus to US	Feb. 07	RE
Biotech firm I-Mab to divest China operations	Feb. 07	RE
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million.	Feb. 06	CI
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	Nov. 02	CI
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	23-10-16	CI
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	23-10-10	CI
AbbVie Terminates $3 Billion Cancer Drug Deal With Biotech Firm I-Mab	23-09-25	MT
I-Mab Regains Global Rights to Lemzoparlimab	23-09-22	CI
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	23-08-31	MT
I-Mab announces an Equity Buyback for $40 million worth of its shares.	23-08-17	CI
I-Mab Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
I-Mab authorizes a Buyback Plan.	23-07-31	CI
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC	23-05-26	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	23-05-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Highlights

Filters